Omeros Shorts Squeezed as Stock Pops

One analyst thinks narsoplimab approval could drive OMER stock higher

Oct 28, 2019 at 2:24 PM
facebook X logo linkedin

Omeros Corporation (NASDAQ:OMER) earlier said it initiated the rolling submission process for a Biologics License Application (BLA) to the U.S. Food and Drug Administration for narsoplimab, its leading antibody to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The therapy already holds an orphan drug designation from the FDA.

Cantor Fitzgerald was quick to weigh in, saying if narsoplimab is approved, it could "generate meaningful revenue for OMER," and "unlock significant value in [the] shares." The brokerage firm -- which has a "overweight" rating and $26 price target on the equity -- said the "risk-reward is to the upside," and that Omeros stock creates a "compelling investment opportunity."

Against this backdrop, OMER stock is up 5.3% to trade at $16.77, set to close above its 30-day moving average for the first time since Sept. 17. The shares have been climbing since a mid-October bounce off familiar support near $14.80, and are now up nearly 50% year-to-date.

Should the shares stay hot, shorts could be encouraged to throw in the towel -- which may translate into buying power for OMER. Short interest jumped 4.1% in the most recent reporting period to 11.78 million shares, representing 25.4% of the stock's available float, or 27.9 times the average daily pace of trading.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI